Efficacy of continuous arterial perfusion chemotherapy combined with transarterial chemoembolization regional arterial thermal perfusion in the treatment of pancreatic cancer with liver metastases

Author:

Zhong Zhuo1,Yang Jian2,Luo Jing-Zi3,Xie Xiong1,Huang Zhi-Mei4,Long De

Affiliation:

1. Oncology Department, Guangzhou Hospital of Integrated Traditional and West Medicine, Guangzhou, China

2. Hepatobiliary Surgery Department, Zhujiang Hospital Affiliated to Southern Medical University, Guangzhou, China

3. Clinical Laboratory Department, Guangzhou Hospital of Integrated Traditional and West Medicine, Guangzhou, China

4. Minimally Invasive Intervention Department, Sun Yat-sen University Cancer Prevention Center, Guangzhou, China

Abstract

Abstract Background The aim of the study was to investigate the efficacy of continuous transcatheter arterial infusion chemotherapy combined with transarterial chemoembolization (TACE) for the treatment of advanced pancreatic cancer with liver metastasis. Methods Sixty patients with advanced pancreatic cancer and liver metastases were enrolled in this study. In the treatment group, 31 patients underwent continuous transcatheter arterial infusion chemotherapy combined with TACE regional arterial thermal perfusion, whereas 29 patients included in the control group received intravenous chemotherapy with gemcitabine and S-1. All patients received maintenance chemotherapy with S-1 after 4 cycles of the study regimen. Treatment efficacy, quality of life, survival, and toxicity were evaluated. Results Efficacy was better in the treatment group than in the control group, as reflected by the objective remission, partial remission, and disease progression rates (all P < 0.05). The Eastern Cooperative Oncology Group and Numerical Rating Scale pain scores were also higher in the treatment group (both P < 0.05). In survival analysis, the 1-year overall survival rates in the treatment and control groups were 64.516% and 10.345%, respectively, whereas the median overall survival times were 16 and 6 months, respectively (both P < 0.05). The 6-month progression-free survival rates in the treatment and control groups were 77.419% and 13.790%, respectively, and the median progression-free survival times were 12 and 3 months, respectively (both P < 0.05). The rates of hematological and nonhematological toxicological adverse effects were also lower in the treatment group (both P < 0.05). Although the rate of liver dysfunction was higher in the treatment group, this finding had no adverse effects on prognosis. Conclusions Continuous transcatheter arterial infusion chemotherapy combined with TACE regional arterial perfusion chemotherapy resulted in better efficacy and safety outcomes in patients with pancreatic cancer and liver metastasis, suggesting its utility as a reference method for the clinical treatment of advanced pancreatic cancer.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference30 articles.

1. Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients With Pancreatic Adenocarcinoma: a surveillance, epidemiology and end results (SEER) analysis;Ann Surg Oncol,2017

2. Feeding arteries of advanced pancreatic cancer: evaluation of 218 patients by digital subtract angiograph;Chin J Clini Med (Chinese),2014

3. Clinical practice guidelines for the interventional treatment of advanced pancreatic cancer (5th edition);J Interv Med,2021

4. Comprehensive guidelines for the diagnosis and treatment of pancreatic cancer (2020 version);Chin J Surg (Chinese),2021

5. Advances in imaging efficacy evaluation of molecular targeted drug therapy for hepatocellular carcinoma;J Imag Res Med Appl (Chinese),2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3